Molecular targets in cancer therapy: the Ron approach

The receptor tyrosine kinase Ron and its ligand, Macrophage Stimulating Protein (MSP), mediate multiple processes involved in the control of cell proliferation, migration and protection from apoptosis. Dysregulated signaling of Ron, due to hyperactivation or loss of negative regulation, is involved...

Full description

Bibliographic Details
Main Authors: Serena Germano, Giovanni Gaudino
Format: Article
Language:English
Published: PAGEPress Publications 2011-12-01
Series:Oncology Reviews
Subjects:
Online Access:http://www.oncologyreviews.org/index.php/or/article/view/158
id doaj-560573f191eb4991a92650aa929213e1
record_format Article
spelling doaj-560573f191eb4991a92650aa929213e12020-11-25T01:24:13ZengPAGEPress PublicationsOncology Reviews1970-55571970-55652011-12-0114Molecular targets in cancer therapy: the Ron approachSerena Germano0Giovanni Gaudino1DISCAFF Department and DFB Center, University of Piemonte Orientale “A. Avogadro”, NovaraDISCAFF Department and DFB Center, University of Piemonte Orientale “A. Avogadro”, NovaraThe receptor tyrosine kinase Ron and its ligand, Macrophage Stimulating Protein (MSP), mediate multiple processes involved in the control of cell proliferation, migration and protection from apoptosis. Dysregulated signaling of Ron, due to hyperactivation or loss of negative regulation, is involved in tumor progression and metastasis. Growing evidence indicates that Ron is abnormally expressed and activated in certain types of primary epithelial cancers (i.e. breast, colon, lung, pancreas, bladder and thyroid), where it critically contributes to the maintenance of tumorigenic and invasive phenotype. Furthermore, a positive association between aberrant Ron expression and aggressive biological indicators as well as a worse clinical outcome have been reported in breast, bladder and thyroid carcinomas. Different approaches have proved effective in targeting receptor activation/expression both in vitro and in animal models, leading to reversion of the tumorigenic phenotype. Altogether these results show that Ron is an attractive molecular target for clinical intervention.http://www.oncologyreviews.org/index.php/or/article/view/158Receptor tyrosine kinase - Ron - Tumorigenesis - Target - Epithelial cancers
collection DOAJ
language English
format Article
sources DOAJ
author Serena Germano
Giovanni Gaudino
spellingShingle Serena Germano
Giovanni Gaudino
Molecular targets in cancer therapy: the Ron approach
Oncology Reviews
Receptor tyrosine kinase - Ron - Tumorigenesis - Target - Epithelial cancers
author_facet Serena Germano
Giovanni Gaudino
author_sort Serena Germano
title Molecular targets in cancer therapy: the Ron approach
title_short Molecular targets in cancer therapy: the Ron approach
title_full Molecular targets in cancer therapy: the Ron approach
title_fullStr Molecular targets in cancer therapy: the Ron approach
title_full_unstemmed Molecular targets in cancer therapy: the Ron approach
title_sort molecular targets in cancer therapy: the ron approach
publisher PAGEPress Publications
series Oncology Reviews
issn 1970-5557
1970-5565
publishDate 2011-12-01
description The receptor tyrosine kinase Ron and its ligand, Macrophage Stimulating Protein (MSP), mediate multiple processes involved in the control of cell proliferation, migration and protection from apoptosis. Dysregulated signaling of Ron, due to hyperactivation or loss of negative regulation, is involved in tumor progression and metastasis. Growing evidence indicates that Ron is abnormally expressed and activated in certain types of primary epithelial cancers (i.e. breast, colon, lung, pancreas, bladder and thyroid), where it critically contributes to the maintenance of tumorigenic and invasive phenotype. Furthermore, a positive association between aberrant Ron expression and aggressive biological indicators as well as a worse clinical outcome have been reported in breast, bladder and thyroid carcinomas. Different approaches have proved effective in targeting receptor activation/expression both in vitro and in animal models, leading to reversion of the tumorigenic phenotype. Altogether these results show that Ron is an attractive molecular target for clinical intervention.
topic Receptor tyrosine kinase - Ron - Tumorigenesis - Target - Epithelial cancers
url http://www.oncologyreviews.org/index.php/or/article/view/158
work_keys_str_mv AT serenagermano moleculartargetsincancertherapytheronapproach
AT giovannigaudino moleculartargetsincancertherapytheronapproach
_version_ 1725118246246416384